抗病毒治疗对慢乙肝相关性肝癌危险因素的影响研究
发布时间：2019-05-28 16:19
【摘要】：目的：研究抗病毒治疗对慢乙肝相关原发性肝癌危险因素的干预作用,从而为临床提供相关数据。 方法：收集青岛市传染病医院2010年2月至2012年6月住院的乙肝相关性肝癌患者病例,共计251例,排除其他病毒性肝炎、酒精性肝炎、自身免疫性肝炎等相关疾病患者病例,将其余232例纳入研究。通过统一编制的调查表记录相关数据信息。根据患者于诊断为HCC前有无抗病毒治疗史将其分为两组,抗病毒治疗组95例,非抗病毒治疗组137例,分析比较两组间各相关高危因素的分布差异。 结果：在抗病毒治疗组与非抗病毒治疗组患者HBV DNA载量、HBeAg性质、HBV感染时间、肝硬化史等分布,差异均有统计学意义(P0.05),抗病毒组患者的HBV DNA载量明显较低,其组内患者被诊断为HCC前的HBV感染时间、肝硬化史均较长；两组间慢乙肝家族史、肝癌家族史差异无统计学意义(P0.05)。 结论：1.抗病毒治疗有利于乙肝相关性肝癌患者的HBeAg发生阴转、降低患者体内HBV DNA载量。2.抗病毒治疗不能降低慢乙肝家族史、肝癌家族史所致HCC发病的风险。3.抗病毒治疗可以有效延缓慢乙肝到HCC的进展,进而或可降低HCC发病率。
[Abstract]:Objective: to study the intervention effect of antiviral therapy on risk factors of primary liver cancer associated with chronic hepatitis B (CHB), so as to provide relevant data for clinic. Methods: a total of 251 patients with hepatitis B associated liver cancer hospitalized in Qingdao Infectious Diseases Hospital from February 2010 to June 2012 were collected and excluded from other viral hepatitis, alcoholic hepatitis, autoimmune hepatitis and other related diseases. The remaining 232 cases were included in the study. The relevant data and information are recorded through the unified questionnaire. According to the history of antiviral therapy before diagnosis of HCC, the patients were divided into two groups: antiviral treatment group (n = 95) and non-antiviral treatment group (n = 137). The distribution differences of related high risk factors between the two groups were analyzed and compared. Results: there were significant differences in the distribution of HBV DNA load, HBeAg nature, HBV infection time and history of liver sclerosis between antiviral group and non-antiviral treatment group (P 0.05). The HBV DNA load of patients in antiviral group was significantly lower than that in non-antiviral group. The patients in the group were diagnosed with HBV infection before HCC and the history of liver sclerosis was longer. There was no significant difference in the family history of chronic hepatitis B and liver cancer between the two groups (P 0.05). Conclusion: 1. Antiviral therapy is beneficial to the negative conversion of HBeAg and the reduction of HBV DNA load in patients with hepatitis B associated liver cancer. 2. Antiviral therapy can not reduce the risk of HCC caused by family history of chronic hepatitis B and liver cancer. 3. Antiviral therapy can effectively delay the progress of chronic hepatitis B to HCC, and then reduce the incidence of HCC.
【学位授予单位】：青岛大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R512.62;R735.7
本文编号：2487194
[Abstract]:Objective: to study the intervention effect of antiviral therapy on risk factors of primary liver cancer associated with chronic hepatitis B (CHB), so as to provide relevant data for clinic. Methods: a total of 251 patients with hepatitis B associated liver cancer hospitalized in Qingdao Infectious Diseases Hospital from February 2010 to June 2012 were collected and excluded from other viral hepatitis, alcoholic hepatitis, autoimmune hepatitis and other related diseases. The remaining 232 cases were included in the study. The relevant data and information are recorded through the unified questionnaire. According to the history of antiviral therapy before diagnosis of HCC, the patients were divided into two groups: antiviral treatment group (n = 95) and non-antiviral treatment group (n = 137). The distribution differences of related high risk factors between the two groups were analyzed and compared. Results: there were significant differences in the distribution of HBV DNA load, HBeAg nature, HBV infection time and history of liver sclerosis between antiviral group and non-antiviral treatment group (P 0.05). The HBV DNA load of patients in antiviral group was significantly lower than that in non-antiviral group. The patients in the group were diagnosed with HBV infection before HCC and the history of liver sclerosis was longer. There was no significant difference in the family history of chronic hepatitis B and liver cancer between the two groups (P 0.05). Conclusion: 1. Antiviral therapy is beneficial to the negative conversion of HBeAg and the reduction of HBV DNA load in patients with hepatitis B associated liver cancer. 2. Antiviral therapy can not reduce the risk of HCC caused by family history of chronic hepatitis B and liver cancer. 3. Antiviral therapy can effectively delay the progress of chronic hepatitis B to HCC, and then reduce the incidence of HCC.
【学位授予单位】：青岛大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R512.62;R735.7
【引证文献】
相关期刊论文 前1条
1 李战英;;乙肝相关性原发性肝癌预后因素分析及抗病毒治疗的临床研究[J];临床合理用药杂志;2017年16期
相关博士学位论文 前1条
1 王绍波;~(18)F-FDG PET/CT早期动态显像在肝癌诊断中的临床应用[D];南方医科大学;2015年
，本文编号：2487194
本文链接：https://www.wllwen.com/yixuelunwen/xiaohjib/2487194.html
最近更新
教材专著
